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1682-606X/Copyright ª 2014, TaiwanSummary Benign prostatic hyperplasia (BPH) is a common benign tumor that develops in
men and is bothersome in elderly patients. The prevalence of lower urinary tract symptoms
in the general population increases with aging. The normal prostate weighs 20  6 g in
men aged 21e30 years. The prevalence of pathological BPH is only 8% at the 4th decade of life;
however, 50% of the male population develop pathological BPH at age 51e60 years. The
average weight of a prostate that is recognized at autopsy as having BPH is 33  16 g. Men
aged 70e79 years are 4.6 times more likely (95% confidence interval, 2.1e10.1) than those
aged 40e49 years to have sought health care because of urinary symptoms. Health care-
seeking behavior is influenced by BPH-related symptoms severity, particularly if the symptoms
are bothersome and interfere with a patient’s daily activities. The progression of BPH is
observed in terms of increased prostate volume and decreased maximal urinary flow rate. In
addition, disease progression increase the risk of acute urinary retention and surgery. On
average, the international prostate symptom score increases 0.18 points/yr, maximal urinary
flow rate decreases by 2%/yr, and median prostate growth increases 1.9%/yr for BPH. In addi-
tion, the accumulative incidence of acute urinary retention is 2.7%. BPH itself is associated
with a deteriorated clinical and symptomatic natural history, and early treatment may benefit
patients with bothersome symptoms of BPH.
Copyright ª 2014, Taiwan Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.eclare no conflicts of interest.
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hyperplasia prior to diagnosis
Benign prostatic hyperplasia (BPH) is the most common
nonmalignant condition of the prostate developing in aging
men. BPH is a major public health concern, causing high
morbidity and substantial worsening of men’s quality of life
(QOL).1 The prevalence rates of BPH mostly depend on the
parameters used in a case definition.2 In Japan, these rates
have been estimated on the basis of the results of
community-based studies.3 Six percent and 12% of Japanese
men in their 60s and 70s, respectively, met all of the
following criteria for BPH: (1) an international prostate
symptom score (IPSS) >7 points; (2) prostate volume (PV)
>20 mL; and (3) peak urinary flow rate (Qmax) <10 mL/s.
Only 2% of men in their 40s and 50s met the aforementioned
criteria.
The principal risk factors for BPH are aging and the
hormone produced from normally functioning testes.
Although no definitive genes responsible for BPH have been
identified, a family history of BPH and molecular abnor-
malities may increase the likelihood of the development of
BPH. Dietary factors, such as isoflavonoids and lignans in
vegetables, grains, and soy, may negatively affect the
development of BPH.1 Furthermore, recent studies have
claimed a relationship between metabolic syndrome and
BPH.4,5 A normal prostate weighs 20  6 g in men aged
21e30 years, and this weight remains essentially constant
with increasing age unless BPH develops. The prevalence of
pathological BPH is 8% in the 4th decade of life; however,
50% of men develop pathological BPH at age 51e60 years.
The average weight of a prostate identified at autopsy as
having BPH is 33  16 g. Only 4% of the prostates in men
older than 70 years weigh >100 g. An analysis of a logistic
growth curve of BPH lesions removed at prostatectomy in-
dicates that the growth of BPH is initiated probably before
the patient is 30 years. The early phase of BPH growth (in
men aged 31e50 years) is characterized by a doubling time
for the tumor weight of 4.5 years. In the mid-phase of BPH
growth (in men aged 51e70 years), the doubling time is 10
years and increases to >100 years in patients older than 70
years.6 BPH is a physiological process that occurs with
aging, regardless of race, ethnicity, or region.6,7 Estimated
rates of prostate growth increased with increasing age.
However, the estimated average annual change was 1.6%
across all age groups. Estimated rates of prostate growth
are high, depending on the baseline PV, with higher growth
rates for men with larger prostates.8
BPH is a progressive disease in a certain proportion ofmen
older than 50 years. Men showing prostate growth are at a
greater risk of symptomatic deterioration. Men with no
prostate growth are significantly more likely to improve
symptomatically.9 The prevalence of lower urinary tract
symptoms (LUTS) in the general population is age-
related.10,11 Longitudinal studies have shown an increase in
the IPSS with aging as a whole9,12 but with simultaneous
decreases in the IPSS in certain subgroups.12,13 Qmax de-
creases with aging,3 and this may be attributable to benign
prostatic obstruction and detrusor underactivity. In addi-
tion, longitudinal studies have confirmed age-related
increases in prostate volume (PV),8,9 although PV decreasedwith aging in a small proportion of men.14 Recent studies
have indicated that PV may increase in men in whom the
prostate has a visible transition zone with a clear border15
and those in whom transrectal ultrasound shows a large
transition zone volume at baseline.16 In general, the rela-
tionship among LUTS, urinary flow rate, and PV is poor in
men presenting at hospitals, but the relationship is modest
in the general population. Prostate enlargement may be
involved in the progression of symptoms of BPH.92. Factors affecting health care-seeking
behavior
A cross-sectional, population-based cohort study in Olms-
ted County, MN, USA, revealed that health care-seeking
behavior is influenced by symptom severity, particularly if
the symptoms are bothersome and interfere with a pa-
tient’s daily activities. While symptom severity is a vital
determinant of health care-seeking behavior in men with
urinary symptoms, age-related factors may drive men to
seek care for urinary symptoms. Men aged 70e79 years
were 4.6 times more likely (95% confidence interval,
2.1e10.1) than those aged 40e49 years to have sought
health care because of urinary symptoms.17 Seventy-six
percent of men who had sought medical care had pros-
tate enlargement, depressed peak urine flow rates, and
moderate-to-severe symptoms of BPH (sensitivity). By
contrast, only 55% of men who did not seek health care for
urinary symptoms had mild symptoms of BPH, normal
prostatic volume, and normal peak urine flow rates (spec-
ificity). Clinical, physiological, and anatomic measures of
prostatism do not adequately distinguish the men who seek
medical care for their urinary symptoms from those who do
not.18
Voiding symptoms may influence health care-seeking
behavior through QOL impairment in Japanese men. The
QOL score revealed more pronounced differences between
men admitted to clinics and community settings than did
the IPSS category.19 The Core Lower Urinary Tract Symptom
Score questionnaire is more comprehensive than the IPSS
questionnaire for symptom assessment in men with various
diseases/conditions, although both questionnaires can
capture LUTS with a potential negative impact on QOL.203. Prediction of symptomatic progression
A systematic review of the placebo arm of clinical trials
related to BPH revealed that disease progression was
relative to increased PV and decreased Qmax. In addition,
disease progression increased the risk of acute urinary
retention (AUR) and surgery.21
Progression may be associated with a higher IPSS, lower
Qmax, increased postvoid residual urine (PVR), and enlarged
PV. According to the Medical Therapy of Prostatic Symptoms
study (MTOPS), the clinical progression of the placebo arm
(nZ 737) was 17%, AURwas 2%, and invasive therapy for BPH
was 5%.22 The results from this study suggested that the risk
factors for clinical progression may include age 62 years,
prostate volume 31 mL, prostate specific antigen1.6 ng/
mL, Qmax <10.6 mL/s, and PVR39 mL.23 However, medical
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vorable conditions and not with a single risk factor. In a
comprehensive analysis of expert opinions, considerable
PVR (>150 mL), poor Qmax (<10 mL/s), and severe symptoms
(total IPSSZ 20e35 points) were the most dominant factors
predicting an elevated risk of disease progression.24
Enlarged prostate and high prostate specific antigen value
were good clinical predictors of AUR and BPH-related sur-
gery. In addition, high PVR should be reconsidered as a
predictor of BPH progression because of evidence from the
results of population-based, longitudinal studies and anal-
ysis of the placebo arm of controlled studies.254. Natural history of BPH after diagnosis
The best method to evaluate the natural history of BPH
after diagnosis is to understand the fate of a watch-
fulewaiting or placebo treatment group. In a community-
based, longitudinal study followed for 12 years, an average
increase in the IPSS of 0.18 points/yr (0.05 points for men in
their 50s to 0.44 points for men in their 70s) was observed.
Qmax decreased 2%/yr, and median prostate growth
decreased 1.9%/yr. In addition, the accumulative incidence
of AUR was 2.7% when monitored for over 4 years.26 In the
placebo-controlled arm of the MTOPS study, evidence
revealed that symptom deterioration (IPSS  4 points) was
the most prevalent progression event (79.5%), with an
accumulative incidence of 14% over a mean follow-up
period of 4.5 years.22
After diagnosis of BPH, self-management intervention,
including lifestyle modification and specific behavioral
changes, such as decreasing fluid intake at bedtime and
avoiding consumption of caffeine and alcohol, may be the
most suitable management strategies that offer an
enhanced clinical response. However, the failure rate at 3
months, 6 months, and 12 months is higher in watch-
fulewaiting patients (40.3% vs. 9.6%; 58.2% vs. 17.8%; and
65.7% vs. 24.6%, respectively) than in patients receiving
active management.27 This evidence indicates that BPH
results in a deteriorated clinical or symptomatic natural
progression, and early treatment may benefit the patients
with bothersome symptoms of BPH.
The Prowess Study revealed that patients with moderate
symptoms of BPH show a significantly greater improvement
with finasteride therapy than those in the placebo group.
The PV decreased 15.3% in the treatment group compared
with that in the placebo group, in which PV increased
approximately 8.9% after 24 months.28 A nationally repre-
sentative database study reported that in addition to a-
blocker therapy, each 30-day delay in the treatment with 5-
a-reductase inhibitors may increase overall clinical pro-
gression (21.1%), AUR (18.6%), and likelihood of prostate-
related surgery (26.7%) within 6 months of follow-up.29
This result indicates that even after receiving early treat-
ment with a-blockers, patients have an elevated risk of
symptomatic progression if they cannot reduce the prostate
size. In the Veterans Affairs Cooperative Study, 24%
watchfulewaiting patients underwent surgery within 3
years of waiting for assignment.30 Based on the natural
history after diagnosis of BPH with or without medical
treatment, monitoring clinical progression should help raiseawareness among clinicians and patients, who should
also remain informed, particularly those receiving
watchfulewaiting treatment.
5. Comments
The prevalence of LUTS in the general population is related
to age. Health care-seeking behavior is influenced by age-
related factors and symptom severity, particularly if they
are bothersome. The disease progression of BPH may be
associated with a higher IPSS, lower Qmax, increased PVR,
and enlarged PV. BPH is associated with a deteriorated
clinical or symptomatic natural progression. Thus, early
treatment may benefit patients with bothersome
symptoms.
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